The presence of TAM and CAF with evidence of activation of the TGF-β1/TAK1/NF-κB/SMAD2 pathway in NB tumours could thus be a biomarker identifying tumours at higher risk of developing drug resistance. This evidence concerns the gene SMAD2 and neuroblastoma.